http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2002061885-A1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D217-26 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D217-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-12 |
| filingDate | 2001-10-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7ee25386e6d3e3b8b21742127b39b8db http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4b9ed9fbcb5e843849f1b3b2972e6e39 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2adc2c050905153683f3f5f74539bc40 |
| publicationDate | 2002-05-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2002061885-A1 |
| titleOfInvention | Tetrahydroisoquinoline-3-carboxylic acid alkoxyguanidines as integrin antagonists |
| abstract | The present invention relates to novel tetrahydroisoquinoline-3-carboxylic acid alkoxyguanidine compounds that are antagonists of alpha V (αv) integrins, for example α v β 3 and α v β 5 integrins, their pharmaceutically acceptable salts, and pharmaceutical compositions thereof. The compounds may be used in the treatment and/or prevention of pathological conditions mediated by α v β 3 and α v β 5 integrins such as tumor growth, metastasis, restenosis, osteoporosis, inflammation, macular degeneration, diabetic retinopathy, rheumatoid arthritis, sickle cell anemia, and in treatment and/or prevention of central nervous system (CNS) related disorders such as neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia, surgery, neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, adverse consequences of overstimulation of one or more excitatory amino acids, anxiety, convulsions, chronic pain, psychosis, schizophrenia, anesthesia, and opiate tolerance. The compounds have the general formula: n n n where R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , m and n are defined herein. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2009034388-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010286112-A1 |
| priorityDate | 2000-08-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 631.